**Abstract**

Post-chemotherapy cognitive impairment is an important problem in cancer survivors. After chemotherapy some patients suffer from memory lapses, have trouble concentrating and remembering details and have problems multitasking. Methotrexate (MTX) is used to treat various forms of cancer as well as rheumatoid arthritis, psoriasis, lupus erythematosus, Crohn's disease and graft --versus-host disease. MTX inhibits adult hippocampal neurogenesis and produces cognitive impairment in rodents. Long-term potentiation (LTP) of synaptic transmission is one of the major cellular mechanisms underlying memory and learning. The objective of the present study was to determine whether MTX treatment impairs hippocampal LTP. Seven week-old, female C57/BL6 mice were given injections once a week for 3 weeks with either saline or MTX (30 mg/kg/i.p). One week after the last injection, hippocampal slices were prepared for electrophysiological recording in field CA1. After 2 h of incubation, field EPSPs elicited by stimulation of the Schaffer collateral pathway were recorded in CA1 stratum radiatum. LTP was induced by theta burst stimulation (TBS; 10 bursts of 4 pulses at 100 Hz delivered at 5 Hz). EPSP slope values were normalized to the average slope of responses recorded during the 10 min baseline, and responses were recorded for at least 30 min after LTP induction. Paired-pulse facilitation, which is widely considered to reflect changes in the probability of transmitter release, was significantly impaired at most interstimulus intervals in slices from MTX-treated mice. LTP was completely absent 30 min after TBS and even the short-term potentiation observed between 0 to 5 min after TBS was markedly reduced in slices from MTX-treated mice. The present study is the first to report that MTX impairs LTP in the hippocampus. These results could account for some of the cognitive impairment reported in patients treated with MTX for a wide variety of clinical conditions.
